American Society of Hematology

Program Schedule for the 2018 ASH Meeting on Lymphoma Biology

Please note: the following information is preliminary and subject to change.

Thursday, August 2, 2018

Welcome, Introductions, and Announcements

Co-Chairs:

Riccardo Dalla-Favera, MD
Columbia University
New York, NY

Kojo S.J. Elenitoba-Johnson, MD
University of Pennsylvania
Philadelphia, PA

Freda K. Stevenson, DPhil
University of Southampton Medical School
Southampton, United Kingdom

Opening Keynote Address: B Cell Antigen Receptor Signaling of Normal and Transformed B Cells

Chair:

Michael Reth
University of Freiburg
Freiburg, Germany

back to top

Friday, August 3, 2018

The Germinal Center as the Target Site

Chair:

Riccardo Dalla-Favera, MD
Columbia University
New York, NY

Speaker:

Jason Cyster, PhD
UCSF Medical Center
San Francisco, CA
Role of Cytokines in Germinal Center Development

Klaus Rajewsky, MD
Harvard Medical School
Boston, Massachusetts
Germinal Center Role in Lymphoma Turmorgenesis

Carola Vinuesa, MD, PhD
Australian National University College of Medicine
Canberra, Australia
Germinal Center Biology

Microenvironment Influences in Lymphoma

Chair:

Freda K. Stevenson, DPhil
University of Southampton Medical School
Southampton, United Kingdom

Speakers:

Hans-Guido Wendel, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Genetic Base Interaction of Microenvironment

Karin Tarte, PhD
INSERM U1236 & CHU Rennes
Rennes, France
Follicular Lymphoma Microenvironment: Role in Pathogenesis and Clinical Impact

Ron Levy, MD
Stanford School of Medicine
Stanford, CA
Combining Intratumoral Injections of TLR Agonists With Checkpoint Antibodies

Genetics and Epigenetics

Chair:

Ari Melnick, MD
Weill Cornell Medical College
New York, NY

Speakers:

Ari Melnick, MD
Weill Cornell Medical College
New York, NY
Epigenetics in Lymphoma

Laura Pasqualucci, MD
Columbia University
New York, NY
Genetic Basis of Epigenetics in Lymphoma

Suzanne Cory
Walter and Eliza Hall Institute of Medical Research
Melbourne, Australia
From Translocation to Therapy: How Understanding the BCL-2 Cell Life/Death Switch Is Leading to More Effective Therapy

back to top

Saturday, August 4, 2018

New Technologies and Diagnostics

Chair:

Ash A. Alizadeh, MD, PhD
Stanford University Medical Center
Stanford, CA

Speakers:

Garry P. Nolan, PhD
Stanford University School of Medicine
Stanford, CA
Single Cell Analysis of Signaling

Ronald N. Germain, MD, PhD
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Bethesda, MD
Single Cell Imaging

Ash A. Alizadeh, MD, PhD
Stanford University Medical Center
Stanford, CA
Circulating Tumor DNA

Molecular Targeting

Chair:

Lou Staudt, MD, PhD
National Cancer Institute, National Institutes of Health
Bethesda, MD

Speakers:

Anthony Letai, MD, PhD
Dana-Farber Cancer Institute
Boston, MA
Mitochondria Tell You What You Need to Know to Treat Lymphoid Cancers

Andreas Strasser, MSc, PhD, FAA
Walter and Eliza Hall Institute of Medical Research,
Melbourne, Australia
Toward Targeting the Pro-Survival BCL-2 Family Members for Cancer Therapy

Roberto Chiarle, MD
Boston Children's Hospital
Boston, MA
Targeted Therapy and Resistance in Lymphoma

Molecular Targeting (Continued)

Chair:

Margaret A. Shipp, MD
Dana-Farber Cancer Institute
Boston, MA

Speakers:

Lou Staudt, MD, PhD
National Cancer Institute, National Institutes of Health
Bethesda, MD
B Cell Receptor Targeting

Margaret A. Shipp, MD
Dana-Farber Cancer Institute
Boston, MA
Checkpoint Inhibitors

Renier J. Brentjens, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY
Chimeric Antigen Receptor T-Cell Therapy

T-Cell Lymphoma

Chair:

Kojo S.J. Elenitoba-Johnson, MD
University of Pennsylvania
Philadelphia, PA

Speakers:

Laurence L. de Leval, MD, PhD
Lausanne University Hospital
Lausanne, Switzerland
Pathology and Genetic Lesions

Teresa Palomero, PhD
Columbia University
New York, NY
Peripheral T Cell Lymphoma

Megan Lim, MD, PhD
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA
Novel Insights Into ALK Mediated Pathogenetic Mechanisms in ALCL

back to top

Sunday, August 5, 2018

B-Cell Malignancies

Chair:

Catherine J. Wu, MD
Dana-Farber Cancer Institute
Boston, MA

Speakers:

Bertrand Nadel, PhD
Centre D'Immunologie De Marseille-Luminy
Marseilles, France
Integrative Single-Cell Analysis: A New Prism to Decipher FL Heterogeneity

Ralf Kuppers, PhD
University of Duisburg - Essen
Essen, Germany
Hodgkin Lymphoma

Elias Campo, MD, PhD
University of Barcelona
Barcelona, Spain
Molecular Heterogeneity in Mantle Cell Lymphoma

Chronic Lymphocytic Leukemia

Chair:

Elias Campo, MD, PhD
University of Barcelona
Barcelona, Spain

Speakers:

Francesco Forconi, MD, PhD
University of Southampton
Southampton, United Kingdom
BCR-Associated Kinase Inhibitors in CLL

Catherine J. Wu, MD
Dana-Farber Cancer Institute
Boston, MA
Clonal Heterogeneity

Davide Rossi, MD, PhD
Oncology Institute of Southern Switzerland
Bellinzona, Switzerland
The Clinical Implications of Gene Mutations in CLL

back to top